These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 12570013)
41. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Kobayashi K; Jodrell DI; Ratain MJ Cancer Surv; 1993; 17():51-78. PubMed ID: 8137353 [TBL] [Abstract][Full Text] [Related]
42. Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children. Patoux A; Bleyzac N; Boddy AV; Doz F; Rubie H; Bastian G; Maire P; Canal P; Chatelut E Eur J Clin Pharmacol; 2001 Jul; 57(4):297-303. PubMed ID: 11549207 [TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Allegaert K; Flint R; Smits A Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):735-749. PubMed ID: 31402708 [No Abstract] [Full Text] [Related]
44. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV; Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395 [TBL] [Abstract][Full Text] [Related]
45. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578 [TBL] [Abstract][Full Text] [Related]
46. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108 [TBL] [Abstract][Full Text] [Related]
47. Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review. Maillard M; Le Louedec F; Thomas F; Chatelut E Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):907-925. PubMed ID: 33016786 [No Abstract] [Full Text] [Related]
48. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Fuchs A; Csajka C; Thoma Y; Buclin T; Widmer N Clin Pharmacokinet; 2013 Jan; 52(1):9-22. PubMed ID: 23196713 [TBL] [Abstract][Full Text] [Related]
49. [Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs]. Chantry AS; Quaranta S; Ciccolini J; Lacarelle B Ann Biol Clin (Paris); 2014; 72(5):527-42. PubMed ID: 25336126 [TBL] [Abstract][Full Text] [Related]
50. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974 [TBL] [Abstract][Full Text] [Related]
51. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Dupuis C; Mercier C; Yang C; Monjanel-Mouterde S; Ciccolini J; Fanciullino R; Pourroy B; Deville JL; Duffaud F; Bagarry-Liegey D; Durand A; Iliadis A; Favre R Anticancer Drugs; 2008 Mar; 19(3):267-73. PubMed ID: 18510172 [TBL] [Abstract][Full Text] [Related]
55. Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. Prémaud A; Rousseau A; Le Meur Y; Venisse N; Loichot C; Turcant A; Hoizey G; Compagnon P; Hary L; Debruyne D; Saivin S; Jacqz-Aigrain E; Marquet P Pharmacol Res; 2010 Feb; 61(2):167-74. PubMed ID: 19800973 [TBL] [Abstract][Full Text] [Related]
56. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. Rodman JH; Furman WL; Sunderland M; Rivera G; Evans WE J Clin Oncol; 1993 Feb; 11(2):287-93. PubMed ID: 8426206 [TBL] [Abstract][Full Text] [Related]
57. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Evans WE Blut; 1988 Jun; 56(6):241-8. PubMed ID: 3289632 [TBL] [Abstract][Full Text] [Related]